DNDenislava Nedeva

Denislava Nedeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Denislava Nedeva has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Questionnaire for Clinical Diagnosis of House Dust Mite’s Allergy Approved by Delphi Consensus

    by Angelica Tiotiu, Fulvio Braido, Krysztof Kowal, Guillermo Guidos Fogelbach, Herberto Chong Neto, Juan Carlos Ivancevich, Daniela Muti, Francisco-Javier Gonzalez-Barcala, Paschalis Steiropoulos, Silviya Novakova, et al.

    Despite house dust mite (HDM)-allergy is the most frequent in the world, no standard questionnaire exists to help physicians in their clinical practice for screening patients with this possible diagnosis. The objective of this survey was to develop a questionnaire that could be used to identify patients with suspicion of HDM-allergy. The survey was conducted using the Delphi methodology. Nineteen international experts in allergology constituted the scientific board who established the items included in the first version of the questionnaire, defined the criteria of the selection for the next steps, and validated the final questionnaire and its interpretation. The initial version of the questionnaire included 15 items. For each item, five answers were suggested graduated by scores from “no importance” to “very high importance.” The predefined conditions for the item selection after each round were a median score ≥ 7 and > 50% of responses according “high importance” and “very high importance.” The electronic survey circulated within the Interasma Scientific Network platform. Eight questions based on the occurrence/worsening of symptoms induced by HDM-allergen exposure meet the survey criteria after the second and the third rounds and were included in the final questionnaire. Binomial answers for each question with 1 point accorded for “Yes” and none for “No” were suggested for the final version with a score ≥ 5 points associated with a high probability for HDM-allergy. By applying the Delphi process, we generated a brief questionnaire with binomial answers, easy to use in clinical practice for screening patients with HDM-allergy.


  • Top Cited Papers
    Open Access

    Impact of Air Pollution on Asthma Outcomes

    by Angelica I. Tiotiu, Plamena Novakova, Denislava Nedeva, Herberto Jose Chong-Neto, Silviya Novakova, Paschalis Steiropoulos, Krzysztof Kowal

    Asthma is a chronic respiratory disease characterized by variable airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Evidence suggests that air pollution has a negative impact on asthma outcomes in both adult and pediatric populations. The aim of this review is to summarize the current knowledge on the effect of various outdoor and indoor pollutants on asthma outcomes, their burden on its management, as well as to highlight the measures that could result in improved asthma outcomes. Traffic-related air pollution, nitrogen dioxide and second-hand smoking (SHS) exposures represent significant risk factors for asthma development in children. Nevertheless, a causal relation between air pollution and development of adult asthma is not clearly established. Exposure to outdoor pollutants can induce asthma symptoms, exacerbations and decreases in lung function. Active tobacco smoking is associated with poorer asthma control, while exposure to SHS increases the risk of asthma exacerbations, respiratory symptoms and healthcare utilization. Other indoor pollutants such as heating sources and molds can also negatively impact the course of asthma. Global measures, that aim to reduce exposure to air pollutants, are highly needed in order to improve the outcomes and management of adult and pediatric asthma in addition to the existing guidelines.


  • Open Access

    Progress in Occupational Asthma

    by Angelica I. Tiotiu, Silviya Novakova, Marina Labor, Alexander Emelyanov, Stefan Mihaicuta, Plamena Novakova, Denislava Nedeva

    Occupational asthma (OA) represents one of the major public health problems due to its high prevalence, important social and economic burden. The aim of this review is to summarize current data about clinical phenotypes, biomarkers, diagnosis and management of OA, a subtype of work-related asthma. Most studies have identified two phenotypes of OA. One is sensitizer-induced asthma, occuring after a latency period and caused by hypersensitivity to high- or low-molecular weight agents. The other is irritant-induced asthma, which can occur after one or more exposures to high concentrations of irritants without latency period. More than 400 agents causing OA have been identified and its list is growing fast. The best diagnostic approach for OA is a combination of clinical history and objective tests. An important tool is a specific inhalation challenge. Additional tests include assessments of bronchial hyperresponsiveness to methacholine/histamine in patients without airflow limitations, monitoring peak expiratory flow at- and off-work, sputum eosinophil count, exhaled nitric oxide measurement, skin prick tests with occupational allergens and serum specific IgE. Treatment of OA implies avoidance of exposure, pharmacotherapy and education. OA is a heterogeneous disease. Mechanisms of its different phenotypes, their diagnosis, role of new biomarkers and treatment require further investigation.


  • Open Access

    A real – life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough

    by Roxana K Mincheva, Tanya Z Kralimarkova, Miroslava Rasheva, Zlatko Dimitrov, Denislava Nedeva, Maria Staevska, Vera Papochieva, Penka Perenovska, Karina Bacheva, Vasil D Dimitrov, et al.

    Different conditions make the proximal airways susceptible to tussigenic stimuli in the chronic cough (CC) syndrome. Leukotrienes can be implicated in the inflammatory mechanism at play in it. Montelukast is a selective cysteinyl-leukotriene receptor antagonist with proven effectiveness in patients with asthma. The aim of our real-life pilot study was to use montelukast to relieve cough symptoms in patients with CC allegedly due to the two frequent causes other than asthma – upper airway cough syndrome and gastroesophageal reflux (GER).